As part of the program, Ceramedix will join the New York City-based incubator JLABS. Ceramedix works to create antibody-based drugs that target diseases involving the microvasculature, according to a May 30 Ceramedix news release.
“As an early-stage company, we believe our residency will serve as a significant catalyst for our research and development work,” Charles Dimmler III, executive chair of Ceramedix, said in the release. “It will also provide our team with access to industry experts and key life science investors offered by the entrepreneurs and innovators ecosystem.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.